Commentaries are short opinion pieces focusing on the latest high-impact research in the field.
Length: up to 1000 words (including any figure and table legends). A maximum of 15 references can be used.
II.2. Submission process
Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf. The submitting author takes responsibility for the article during submission.
To facilitate rapid publication and to minimize administrative costs, Biomedical Research and Therapy prefers online submission.
The following word processor file formats are acceptable for the main manuscript document:
ï¿½ Microsoft word (DOC, DOCX)
ï¿½ Rich text format (RTF)
ï¿½ Portable document format (PDF)
II.3. Preparing main manuscript text
General guidelines of the journal's style and language are given below.
Manuscript sections for Commentaries Manuscripts for Commentaries submitted to Biomedical Research & Therapy should be divided into the following sections (in this order):
ï¿½ Title page
ï¿½ Main Text
ï¿½ List of abbreviations used (if any)
ï¿½ Competing interests
ï¿½ Authors' contributions
ï¿½ Authors' information
ï¿½ Illustrations and figures (if any)
ï¿½ Tables and captions (if any)
The Accession Numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets and include the corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116].
The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot).
This should list the title of the article, the full names, institutional addresses, and email addresses for all authors.
The corresponding author should also be indicated. A short title of not more than 50 characters excluding spaces should be provided in addition to the full title.
This should not exceed 100 words. Please do not use abbreviations or cite references in the abstract.
Three to ten keywords representing the main content of the article.
This should contain the body of the article, and may also be broken into subsections with short, informative headings.
This should state clearly the main conclusions of the article and give a clear explanation of the importance and relevance of the software.
LIST OF ABBREVIATIONS
If abbreviations are used in the text they should be defined in the text at first use, and a list of abbreviations can be provided, which should precede the competing interests and authors' contributions.
A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with other people or organizations. Authors must disclose any financial competing interests; they should also reveal any non-financial competing interests that may cause them embarrassment were they to become public after the publication of the manuscript.
Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.
When completing your declaration, please consider the following questions:
Financial competing interests
ï¿½ In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)? If so, please specify.
ï¿½ Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? If so, please specify.
ï¿½ Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
ï¿½ Do you have any other financial competing interests? If so, please specify.
Non-financial competing interests
Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify.
If you are unsure as to whether you, or one your co-authors, has a competing interest please discuss it with the editorial office.
Please acknowledge anyone who contributed towards the article by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the criteria for authorship.
Please also include the source(s) of funding for each author, and for the manuscript preparation. Authors must describe the role of the funding body, if any, in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.
Please also acknowledge anyone who contributed materials essential for the study.
If a language editor has made significant revision of the manuscript, we recommend that you acknowledge the editor by name, where possible. The role of a scientific (medical) writer must be included in the acknowledgements section, including their source(s) of funding. We suggest wording such as 'We thank Jane Doe who provided medical writing services on behalf of XYZ Pharmaceuticals Ltd.'
Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements section.
Endnotes should be designated within the text using a superscript lowercase letter and all notes (along with their corresponding letter) should be included in the Endnotes section. Please format this section in a paragraph rather than a list.
BMRAT uses the reference style of VANCOUVER style. You should use reference manager software such as Endnote during the manuscript preparation. And then format reference with Vancouver style.
Vancouver is a numbered referencing style commonly used in medicine and science, and consists of:
It follows rules established by the International committee of Medical Journal Editors, now maintained by the U.S. National Library of Medicine. It is also known as Uniform Requirements for Manuscripts submitted to Biomedical Journals.
PREPARING ILLUSTRATIONS AND FIGURES
Illustrations should be provided as separate files, not embedded in the text file.
Each figure should include a single illustration and should fit on a single page in portrait format.
If a figure consists of separate parts, it is important that a single composite illustration file be submitted which contains all parts of the figure.
There is no charge for the use of color figures.
The following file formats can be accepted:
ï¿½ PDF (preferred format for diagrams)
ï¿½ DOCX/DOC (single page only)
ï¿½ PPTX/PPT (single slide only)
ï¿½ PNG (preferred format for photos or images)
Biomedical Research & Therapy will edit all figures supplied by the author. For this reason it is especially important that authors should supply figures in vector form, to facilitate such editing.
The legends should be included in the main manuscript text file at the end of the document, rather than being a part of the figure file.
For each figure, the following information should be provided: Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed legend, up to 300 words.
Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce figures or tables that have previously been published elsewhere.
Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.).
Tables should also have a title (above the table) that summarizes the whole table; it should be no longer than 15 words. Detailed legends may then follow, but they should be concise.
Tables should always be cited in text in consecutive numerical order. Smaller tables considered to be integral to the manuscript can be pasted into the end of the document text file, in A4 portrait or landscape format.
These will be typeset and displayed in the final published form of the article. Such tables should be formatted using the 'Table object' in a word processing program to ensure that columns of data are kept aligned when the file is sent electronically for review; this will not always be the case if columns are generated by simply using tabs to separate text. Columns and rows of data should be made visibly distinct by ensuring that the borders of each cell display as black lines. Commas should not be used to indicate numerical values. Color and shading may not be used; parts of the table can be highlighted using symbols or bold text, the meaning of which should be explained in a table legend.
Tables should not be embedded as figures or spreadsheet files. Larger datasets or tables too wide for a landscape page can be uploaded separately as additional files.
Additional files will not be displayed in the final, laid-out PDF of the article, but a link will be provided to the files as supplied by the author.
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls ) or comma separated values (.csv).
As with all files, please use the standard file extensions